Anuh Pharma
- Market cap
- ₹ 754 Cr.
- P/E
- 17.4x
- P/B
- 2.24x
- 52-week range
- 67 – 99.5
- ROE
- 11%
- ROCE
- 15%
- Dividend yield
- 1.9%
- Debt / equity
- 0
- Sector
- Pharmaceuticals & Biotechnology
- Industry
- Pharmaceuticals
- Listed on
- NSE, BSE
About
Anuh Pharma Limited is engaged in the business of manufacturing and selling bulk drugs and chemicals. The Company's products include active pharmaceutical ingredients and corticosteroids. Its active pharmaceutical ingredients include macrolides, anti-TB, anti-malarial, antibacterial, anti-hypertension, expectorant, quinolones, intermediates and under development. Its macrolides products include erythromycin, erythromycin ethyl succinate, erythromycin stearate, erythromycin estolate, erythromycin propionate, erythromycin phosphate, and others. Its anti-malarial products include sulfadoxine, pyrimethamine, and others. The Company's anti-hypertension products include losartan potassium, telmisartan and atorvastatin calcium. The Company's corticosteroids include anti-inflammatory, immunosuppressant, anti-pruritic, anti-mitotic, antihistamines and under development. Its anti-inflammatory products include dexamethasone Na phosphate, mometasone furoate and clobetasol butyrate.
Quick check
The five things to look at first. Open one for more.
Compared with its industry
Pharmaceuticals: 221 companies →Anuh Pharma against the typical company in its industry. The rank is out of the companies that report each figure; green means the better quarter of the pack, red the worse quarter.
- Valuation (P/E)17.4 against a typical 33.2: cheaper than most peers (1st = cheapest).47th of 220
- Sales growth+4.3% against a typical +15.6% from a year earlier.138th of 197
- Profit growth+37.5% against a typical +18.9% from a year earlier.63rd of 160
- Share price, 3 months−0.7% against a typical −0.8%.100th of 200
- Size₹ 754.3 Cr. market value against a typical ₹ 507.7 Cr. (1st = largest).93rd of 199
Credit ratings
Every rating action on file, newest first, including reaffirmations. Open a row for the agency's reasoning. All credit rating updates
Adequate safety
Rated A- by ICRA- No warnings from the agency.
| Agency | Current rating | Outlook | As of |
|---|---|---|---|
| ICRA | [ICRA]A- | Positive | 15 Sep 2025 |
| Rating | Details | |||||
|---|---|---|---|---|---|---|
| 15 Sep 2025 | Reaffirmed | [ICRA]A- | — | ICRA | ₹ 245 Cr. |
Board meetings
Results dates and other board meetings. Full calendar
| Details | ||
|---|---|---|
| 30 Oct 2026Upcoming | Financial Results/Other business matters | To consider and approve the financial results for the period ended September 30, 2026 and other business matters |
| 7 Aug 2026 | Financial Results/Other business matters | To consider and approve the Unaudited financial results for the period ended Jun 30, 2026 and other business matters. |
| 20 May 2026 | Financial Results/Dividend/Other business matters | To consider and approve the financial results for the period ended March 31, 2026, dividend and other business matters |
| 6 Feb 2026 | Financial Results/Other business matters | ANUH PHARMA LIMITED has informed the Exchange about Board Meeting to be held on 06 Feb 2026 to consider and approve the quarterly Unaudited Financial results of the Company for the period ended December 2025 and Other business |
| 7 Nov 2025 | Financial Results/Other business matters | To consider and approve the Un-Audited financial results for the Quarter and Half Year ended September 30, 2025 and other business matters |
| 8 Aug 2025 | Financial Results/Other business matters | To consider and approve the Quarterly Unaudited financial results of the Company for the period ended Jun 30, 2025 and other business matters |
| 23 May 2025 | Financial Results/Dividend/Bonus/Other business matters | To consider and approve the financial results for the period ended March 31, 2025, dividend, bonus and other business matters |
Financials
Standalone figures in ₹ crore.
| ₹ Cr. | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 150 | 172 | 164 | 138 | 166 | 160 | 198 | 186 | 186 | 197 | 202 | 194 |
| Expenses | 132 | 148 | 145 | 127 | 149 | 145 | 179 | 176 | 174 | 178 | 182 | 178 |
| Operating Profit | 18 | 24 | 19 | 11 | 17 | 15 | 19 | 10 | 12 | 19 | 20 | 16 |
| OPM % | 12% | 14% | 12% | 8% | 10% | 9% | 9% | 6% | 6% | 10% | 10% | 8% |
| Other Income | 2 | 4 | 3 | 4 | 3 | 1 | 1 | 3 | 1 | 2 | −1 | 3 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 2 | 2 | 2 | 2 | 2 | 2 | 3 | 3 | 3 | 3 | 3 | 2 |
| Profit before tax | 18 | 25 | 20 | 12 | 18 | 13 | 17 | 11 | 10 | 18 | 16 | 17 |
| Tax % | 23% | 24% | 22% | 22% | 17% | 22% | 28% | 24% | 23% | 25% | 25% | 32% |
| Net Profit | 14 | 19 | 15 | 10 | 15 | 10 | 12 | 8 | 8 | 13 | 12 | 11 |
| EPS in Rs | 1.38 | 1.91 | 1.53 | 0.95 | 1.5 | 1.03 | 1.24 | 0.83 | 0.76 | 1.34 | 1.17 | 1.14 |
Growth and returns
Compounded yearly rates over each period.
- 10 Years
- 9%
- 5 Years
- 12%
- 3 Years
- 14%
- TTM
- 10%
- 10 Years
- 4%
- 5 Years
- 10%
- 3 Years
- 3%
- TTM
- −4%
- 10 Years
- 5%
- 5 Years
- 5%
- 3 Years
- 5%
- TTM
- —
- 10 Years
- 13%
- 5 Years
- 14%
- 3 Years
- 14%
- TTM
- —
P/E and EPS over time
Daily P/E and trailing 12-month EPS. EPS updates with each result.
Peers
Listed companies in the same business.
| Anuh Pharma | ₹ 78.58 | ₹ 754 Cr. | 17.4x | 2.2x | 11% | — |
| Sun Pharmaceutical Industries | ₹ 1,743.00 | ₹ 4,18,194 Cr. | 38.4x | 5.6x | 14.2% | 19.1% |
| Divi's Laboratories | ₹ 8,984.00 | ₹ 2,38,497 Cr. | 73.3x | 11.5x | 16.2% | 24.3% |
| Torrent Pharmaceuticals | ₹ 4,482.00 | ₹ 1,70,475 Cr. | 72.7x | 19.2x | 27.1% | 15.3% |
| Cipla | ₹ 1,337.00 | ₹ 1,08,011 Cr. | 27.6x | 3.3x | 11.8% | 13.7% |
| Zydus Lifesciences | ₹ 1,127.85 | ₹ 1,12,503 Cr. | 21.2x | 4.2x | 19.7% | 18.5% |
Management
- Darshan D. Rampariya
- Chief Financial Officer
- Manan Jayesh Vadhan
- Compliance Officer, Company Secretary
- Ritesh Bipin Shah
- Joint Managing Director, Executive Director
- Vivek Bipin Shah
- Joint Managing Director, Executive Director
Prices are delayed and for information only. Nothing on this page is investment advice.